These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34560264)

  • 1. Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor.
    Wu Y; Duan Q; Zou Y; Zhu Q; Xu Y
    Bioorg Med Chem Lett; 2021 Nov; 52():128373. PubMed ID: 34560264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors.
    Steeneck C; Kinzel O; Anderhub S; Hornberger M; Pinto S; Morschhaeuser B; Albers M; Sonnek C; Czekańska M; Hoffmann T
    Bioorg Med Chem Lett; 2021 Feb; 33():127744. PubMed ID: 33333163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy.
    Liu C; Nan Y; Xia Z; Gu K; Chen C; Dong X; Ju D; Zhao W
    Bioorg Med Chem Lett; 2020 Apr; 30(8):127038. PubMed ID: 32088128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 5-(N-hydroxycarbamimidoyl) benzofuran derivatives as novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
    Jung J; Yoon H; Sohn TI; Jang K; Yoo Y; Jeong I; Shin JE; Lee JH; Ann J; Lee J
    Bioorg Med Chem Lett; 2021 May; 40():127963. PubMed ID: 33741464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold.
    Kinzel O; Steeneck C; Anderhub S; Hornberger M; Pinto S; Morschhaeuser B; Albers M; Sonnek C; Wang Y; Mallinger A; Czekańska M; Hoffmann T
    Bioorg Med Chem Lett; 2021 Feb; 33():127738. PubMed ID: 33316404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent IDO1 inhibitors derived from tryptophan using scaffold-hopping and structure-based design approaches.
    Zou Y; Wang Y; Wang F; Luo M; Li Y; Liu W; Huang Z; Zhang Y; Guo W; Xu Q; Lai Y
    Eur J Med Chem; 2017 Sep; 138():199-211. PubMed ID: 28667875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1.
    Paul S; Roy A; Deka SJ; Panda S; Trivedi V; Manna D
    Eur J Med Chem; 2016 Oct; 121():364-375. PubMed ID: 27267006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays.
    Ge H; Mao L; Zhao J; Wang Y; Shi D; Yang X; Wang X; Liu H; Yao X
    J Comput Aided Mol Des; 2021 May; 35(5):679-694. PubMed ID: 33905074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of immunosuppressive indoleamine 2,3-dioxygenase by targeting the heme and apo-form.
    Pradhan N; Akhtar N; Nath B; Peña-García J; Gupta A; Pérez-Sánchez H; Kumar S; Manna D
    Chem Commun (Camb); 2021 Jan; 57(3):395-398. PubMed ID: 33326535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.
    Hamilton MM; Mseeh F; McAfoos TJ; Leonard PG; Reyna NJ; Harris AL; Xu A; Han M; Soth MJ; Czako B; Theroff JP; Mandal PK; Burke JP; Virgin-Downey B; Petrocchi A; Pfaffinger D; Rogers NE; Parker CA; Yu SS; Jiang Y; Krapp S; Lammens A; Trevitt G; Tremblay MR; Mikule K; Wilcoxen K; Cross JB; Jones P; Marszalek JR; Lewis RT
    J Med Chem; 2021 Aug; 64(15):11302-11329. PubMed ID: 34292726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.
    Weng T; Qiu X; Wang J; Li Z; Bian J
    Eur J Med Chem; 2018 Jan; 143():656-669. PubMed ID: 29220788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The [1,2,4]Triazolo[4,3-a]pyridine as a New Player in the Field of IDO1 Catalytic Holo-Inhibitors.
    Fallarini S; Bhela IP; Aprile S; Torre E; Ranza A; Orecchini E; Panfili E; Pallotta MT; Massarotti A; Serafini M; Pirali T
    ChemMedChem; 2021 Nov; 16(22):3439-3450. PubMed ID: 34355531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel High Throughput Virtual Screening Protocol to Discover New Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
    Xu H; Song Y; Yang Q
    Chem Pharm Bull (Tokyo); 2017; 65(8):714-717. PubMed ID: 28768924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
    Fung SP; Wang H; Tomek P; Squire CJ; Flanagan JU; Palmer BD; Bridewell DJ; Tijono SM; Jamie JF; Ching LM
    Bioorg Med Chem; 2013 Dec; 21(24):7595-603. PubMed ID: 24262887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase*.
    Ortiz-Meoz RF; Wang L; Matico R; Rutkowska-Klute A; De la Rosa M; Bedard S; Midgett R; Strohmer K; Thomson D; Zhang C; Mebrahtu M; Guss J; Totoritis R; Consler T; Campobasso N; Taylor D; Lewis T; Weaver K; Muelbaier M; Seal J; Dunham R; Kazmierski W; Favre D; Bergamini G; Shewchuk L; Rendina A; Zhang G
    Chembiochem; 2021 Feb; 22(3):516-522. PubMed ID: 32974990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the discovery and development of selective heme-displacing IDO1 inhibitors.
    Sun L
    Expert Opin Drug Discov; 2020 Oct; 15(10):1223-1232. PubMed ID: 32568559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation.
    Xu X; Ren J; Ma Y; Liu H; Rong Q; Feng Y; Wang Y; Cheng Y; Ge R; Li Z; Bian J
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):250-263. PubMed ID: 30734612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
    Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
    Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form.
    Nelp MT; Kates PA; Hunt JT; Newitt JA; Balog A; Maley D; Zhu X; Abell L; Allentoff A; Borzilleri R; Lewis HA; Lin Z; Seitz SP; Yan C; Groves JT
    Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3249-3254. PubMed ID: 29531094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
    Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
    Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.